证券代码：301075 证券简称：多瑞医药 公告编号：2025-097 西藏多瑞医药股份有限公司 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会没有出现否决议案的情形； 2.本次股东会没有涉及变更前次股东会决议的情形。 一、会议召开和出席情况 西藏多瑞医药股份有限公司（以下简称"公司"或"多瑞医药"） 2025年第一次临时股东会通知于2025年10月14日以公告形式发出， 具体内容详见当日公司于中国证监会指定信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）发布的公告。 （一）会议召开情况 1、会议召开时间： （1）现场会议时间：2025 年 10 月 30 日（星期四）14:30 （2）网络投票时间：2025 年 10 月 30 日（星期四） 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025 年 10 月 30 日 09:15-09:25，09:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网系统（http://wltp.c ...

Core Viewpoint - The company, Duorui Pharmaceutical, emphasizes its commitment to establishing a robust corporate governance structure and enhancing communication with investors, particularly small and medium shareholders [1] Group 1: Corporate Governance - The company will adhere to the requirements of the Company Law, the Code of Corporate Governance for Listed Companies, and other relevant laws and regulations to establish a governance structure composed of the shareholders' meeting, board of directors, and management [1] - There will be efforts to further improve related systems to ensure effective governance [1] Group 2: Investor Communication - The company plans to strengthen communication with investors through various channels, actively engaging with shareholders, especially small and medium shareholders, to gather their opinions and demands [1] - The company commits to timely responses to concerns raised by small and medium shareholders [1] Group 3: Information Disclosure - The company aims to continuously enhance the quality of information disclosure, ensuring that it is truthful, accurate, complete, timely, and fair [1]

Core Viewpoint - Duori Pharmaceutical announced on October 24 that the share transfer requires approval from the company's shareholders meeting and compliance confirmation from the Shenzhen Stock Exchange, highlighting the need for adherence to legal procedures and information disclosure obligations to protect the interests of the company and minority investors [1] Summary by Relevant Sections - **Share Transfer Process** - The share transfer is subject to approval from the shareholders meeting and may require additional regulatory approvals [1] - **Compliance and Legal Obligations** - The company emphasizes the importance of following relevant laws and regulations in the process, ensuring that all legal procedures are strictly adhered to [1] - **Investor Communication** - Duori Pharmaceutical will keep investors informed of any developments through official announcements, reinforcing its commitment to transparency [1]

Core Viewpoint - The company emphasizes the importance of market value management and plans to enhance information disclosure, optimize market value management mechanisms, and improve communication with investors to convey the company's value effectively [1] Group 1 - The company is committed to improving its market value management efforts [1] - The company will continue to enhance the quality of information disclosure [1] - The company aims to optimize its market value management mechanisms [1] Group 2 - The company intends to improve the quality of communication and interaction with investors [1] - The company will ensure timely communication of its value to the capital market [1]

Core Viewpoint - The company, Tibet Duori Pharmaceutical Co., Ltd., has approved a cash management plan to utilize idle self-owned funds of up to 150 million yuan to enhance fund efficiency and achieve asset preservation and appreciation [1][2]. Investment Plan Details - The cash management plan is designed with the principles of prioritizing safety, matching liquidity, and supplementing returns, with a maximum investment amount of 150 million yuan and a strict investment period not exceeding 12 months [2]. - The funds will be invested in low-risk products issued by banks or other financial institutions, explicitly excluding stocks, derivatives, and unsecured bonds [3]. Funding Source and Decision Mechanism - The cash management funds will solely come from the company's idle self-owned funds, without involving raised or borrowed funds. The board has authorized management to make investment decisions within the set limits, with the finance department responsible for specific operations [4]. Risk Control and Supervision Mechanism - A multi-layered risk prevention system has been established, including a product selection mechanism that limits investments to low-risk products from state-owned banks or mainstream financial institutions, a dynamic monitoring mechanism for real-time tracking of product value changes, and an internal supervision mechanism for regular checks by independent directors and the supervisory board [5]. Impact on Company Operations - The cash management plan will not affect the company's main business operations, as it is implemented while ensuring the funding needs for daily production and project construction. The scientific allocation of idle funds is expected to enhance fund yield and further increase company profits, creating more value for shareholders [6]. Validity of the Resolution - The resolution is valid for 12 months from the date of board approval, with specific investment products to be selected based on market conditions [7].

Core Viewpoint - Duori Pharmaceutical (301075.SZ) reported a significant decline in revenue and an increase in net losses for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 137 million yuan, representing a year-on-year decrease of 43.07% [1] - The net loss attributable to shareholders of the listed company was 79.7277 million yuan [1] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 84.9485 million yuan [1] - The basic loss per share was 1.0064 yuan [1]

Core Viewpoint - Duori Pharmaceutical (301075.SZ) reported a significant decline in revenue and an increase in net losses for the third quarter of the year [1] Financial Performance - The company recorded a revenue of 137 million yuan for the first three quarters, representing a year-on-year decrease of 43.07% [1] - The net loss for the period amounted to 79.72 million yuan, with a non-recurring net loss of 84.95 million yuan [1] - Basic earnings per share were reported at -1.0064 yuan [1]

Core Viewpoint - Duori Pharmaceutical reported a significant decline in both revenue and net profit for the third quarter and the first three quarters of the year, indicating potential challenges in its financial performance and market position [1] Financial Performance Summary - The company's revenue for the third quarter was 30.4254 million yuan, a year-on-year decrease of 39.32% [1] - The net profit for the third quarter was a loss of 37.2241 million yuan, representing a decline of 169.69% [1] - For the first three quarters, the total revenue was 137 million yuan, down 43.07% year-on-year [1] - The net profit for the first three quarters showed a loss of 79.7277 million yuan, which is a decrease of 27.23% compared to the previous year [1]

中信证券股份有限公司 关于西藏多瑞医药股份有限公司 部分募投项目终止、结项并将剩余募集资金 偿还银行贷款和永久补充流动资金的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为西藏 多瑞医药股份有限公司（以下简称"多瑞医药"或"公司"）首次公开发行股票 并在深圳证券交易所创业板上市的保荐机构，根据《证券发行上市保荐业务管理 办法》《上市公司募集资金监管规则》和《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等有关规定，就多瑞医药部分募投项目 终止、结项并将剩余募集资金偿还银行贷款和永久补充流动资金的事项进行了核 查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意西藏多瑞医药股份有限公司首次公开 发行股票注册的批复》（证监许可〔2021〕2760 号）同意注册，多瑞医药首次 公开发行人民币普通股（A 股）股票 2,000.00 万股，每股面值 1.00 元，每股发 行价格为人民币 27.27 元，募集资金总额为人民币 54,540.00 万元，扣除相关发 行费用后实际募集资金净额为人民币 48,204.97 万元。上述募集资金到位情况经 ...

西藏多瑞医药股份有限公司 投资者关系管理制度 第一章 总则 第一条 为进一步完善西藏多瑞医药股份有限公司（以下简称"公司"）治理结构， 规范公司投资者关系工作，加强公司与投资者和潜在投资者（以下统称"投资者"）之 间的沟通，加深投资者对公司的了解和认同，促进公司和投资者之间长期、稳定的良 好关系，提升公司的诚信度、核心竞争能力和持续发展能力，实现公司价值最大化和 股东利益最大化，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民 共和国证券法》（以下简称《证券法》）、《上市公司与投资者关系工作指引》及《国务 院关于进一步提高上市公司质量的意见》《关于进一步加强资本市场中小投资者合法权 益保护工作的意见》《关于全面推进证券期货纠纷多元化解机制建设的意见》等法律、 法规、规章、规范性文件及《西藏多瑞医药股份有限公司章程》（以下简称"公司章程"） 的规定，结合公司实际情况，特制定本制度。 第二条 投资者关系管理是指上市公司通过便利股东权利行使、信息披露、互动交 流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对上市公 司的了解和认同，以提升上市公司治理水平和企业整体价值，实现尊重投资者 ...